Literature DB >> 25246301

Outcomes after early administration of plasma exchange in pediatric central nervous system inflammatory demyelination.

Sandra Bigi1, Brenda Banwell2, E Ann Yeh3.   

Abstract

The use of plasma exchange has been described in steroid-refractory central nervous system inflammatory demyelination in adults, but less has been published regarding its use in children and adolescents. We describe 12 children treated with plasma exchange for acute severe central nervous system inflammatory demyelination. The clinical attack leading to plasma exchange included symptomatic spinal cord lesions in 10 and symptomatic brainstem lesions in 2 children. Diagnosis was acute transverse myelitis in 6, relapsing-remitting multiple sclerosis in 5, and acute disseminated encephalomyelitis in 1 child. Adverse events related to plasma exchange necessitating intervention were observed in 3 children. Median Expanded Disability Status Scale score at plasma exchange start was 7.5 (range 4-9.5). At 3 months, 7 children were ambulatory without aid (Expanded Disability Status Scale score of ≤4). This retrospective study suggests that plasma exchange can be effective in ameliorating symptoms in severe pediatric central nervous system inflammatory demyelination, although lack of randomization or control group limits the ability to attribute this outcome entirely to plasma exchange.
© The Author(s) 2014.

Entities:  

Keywords:  central nervous system inflammatory demyelination; pediatric; plasma exchange

Mesh:

Year:  2014        PMID: 25246301     DOI: 10.1177/0883073814545883

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  9 in total

Review 1.  Improving Outcomes in Pediatric Multiple Sclerosis: Current and Emerging Treatments.

Authors:  Colin Wilbur; E Ann Yeh
Journal:  Paediatr Drugs       Date:  2019-06       Impact factor: 3.930

Review 2.  Paediatric Multiple Sclerosis: Update on Diagnostic Criteria, Imaging, Histopathology and Treatment Choices.

Authors:  I-Jun Chou; Huei-Shyong Wang; William P Whitehouse; Cris S Constantinescu
Journal:  Curr Neurol Neurosci Rep       Date:  2016-07       Impact factor: 5.081

3.  A Longitudinally Extensive Spinal Cord Lesion Restricted to Gray Matter in an Adolescent Male.

Authors:  Danielle Golub; Faith Williams; Taylor Wong; Nishanth Iyengar; Hannah Jolley; Sakinah Sabadiah; David Rhee; Gabrielle Gold-von Simson
Journal:  Front Neurol       Date:  2019-03-20       Impact factor: 4.003

4.  Therapeutic plasma exchange for pediatric nonrenal disease indications and outcomes: A single-center experience.

Authors:  Saravanan Margabandhu; Suchitra Ranjit; Indira Jayakumar; Chitra Sundaramoorthy; Mahesh Janarthanan; Jayakumar Reddy; Meena Thiagarajan; Shyamala Jayamoorthy; Latha Vishwanathan
Journal:  Asian J Transfus Sci       Date:  2018 Jul-Dec

Review 5.  Therapeutic Apheresis in Acute Relapsing Multiple Sclerosis: Current Evidence and Unmet Needs-A Systematic Review.

Authors:  Leoni Rolfes; Steffen Pfeuffer; Tobias Ruck; Nico Melzer; Marc Pawlitzki; Michael Heming; Marcus Brand; Heinz Wiendl; Sven G Meuth
Journal:  J Clin Med       Date:  2019-10-04       Impact factor: 4.241

6.  Safety and efficacy of plasma exchange in pediatric transverse myelitis.

Authors:  Daniel K Noland; Benjamin M Greenberg
Journal:  Neurol Clin Pract       Date:  2018-08

Review 7.  Acute Transverse Myelitis in Children, Literature Review.

Authors:  Azita Tavasoli; Aidin Tabrizi
Journal:  Iran J Child Neurol       Date:  2018

8.  Role of Methyl Prednisolone in Longitudinal Extensive Transverse Myelitis (LETM) in Children.

Authors:  Muhammad Azeem Ashfaq; Iram Javed; Muhammad Arshad; Muhammad Rizwan Yaseen
Journal:  Pak J Med Sci       Date:  2020 Mar-Apr       Impact factor: 1.088

9.  Recommendations for the Diagnosis and Treatment of Multiple Sclerosis Relapses.

Authors:  Cristina Ramo-Tello; Yolanda Blanco; Luis Brieva; Bonaventura Casanova; Eva Martínez-Cáceres; Daniel Ontaneda; Lluís Ramió-Torrentá; Àlex Rovira
Journal:  J Pers Med       Date:  2021-12-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.